Skip to main content
SpringerLink
Log in

Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma

  • Original Article
  • Published:
Tumor Biology

Abstract

Patients with osteosarcoma have poor prognosis and are often at high risk of death. Identification of prognostic biomarkers for osteosarcoma may aid in improving the survival. Hyperuricemia had been suggested as a poor prognostic factor of several cancers, but the prognostic role of hyperuricemia in osteosarcoma patients had not been assessed. In the present study, we investigated the prognostic role of hyperuricemia at baseline on the overall survival of patients with osteosarcoma. Sixty osteosarcoma patients with hyperuricemia were matched (1:2) to 120 osteosarcoma patients without hyperuricemia with similar age and gender. Data from those patients with osteosarcoma were evaluated retrospectively. The role of hyperuricemia on overall survival was firstly analyzed using the Kaplan-Meier method. Univariate and multivariate Cox regression models were also used to further evaluate the prognostic significance of hyperuricemia. None of the clinicopathological parameters except distant metastasis was associated with hyperuricemia. Kaplan-Meier method showed that patients with hyperuricemia had shorter overall survival compared with those with normouricemia (P < 0.0001, log-rank test). In univariate analysis, hyperuricemia was associated with poorer overall survival in osteosarcoma patients (HR = 2.71, 95 % CI 1.75–4.20; P < 0.0001). In the multivariate analysis, after adjusting for age, gender, serum alkaline phosphatase, stage, tumor size, and metastasis, hyperuricemia was independently associated with poorer overall survival in osteosarcoma patients (HR = 2.28, 95 % CI 1.41–3.69; P = 0.001). In conclusion, hyperuricemia at baseline is associated with poorer overall survival in osteosarcoma patients, and it has an adverse impact on the prognosis of osteosarcoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65–92.

    Article  PubMed  Google Scholar 

  2. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(7):vii320–5.

    PubMed  Google Scholar 

  3. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–18.

    PubMed  Google Scholar 

  4. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47:2431–45.

    Article  CAS  PubMed  Google Scholar 

  5. Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, et al. Palliative therapy for osteosarcoma. Expert Rev Anticancer Ther. 2011;11:217–27.

    Article  PubMed  Google Scholar 

  6. Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian sarcoma group study. Ann Oncol. 2012;23:508–16.

    Article  CAS  PubMed  Google Scholar 

  7. Matsunobu A, Imai R, Kamada T, Imaizumi T, Tsuji H, Tsujii H, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012;118:4555–63.

    Article  PubMed  Google Scholar 

  8. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol. 2009;35:1030–6.

    Article  CAS  PubMed  Google Scholar 

  9. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134:281–97.

    Article  CAS  PubMed  Google Scholar 

  10. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13–23.

    Article  CAS  PubMed  Google Scholar 

  11. Alvarez-Lario B, Macarron-Vicente J. Is there anything good in uric acid? QJM. 2011;104:1015–24.

    Article  CAS  PubMed  Google Scholar 

  12. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26:186–91.

    Article  CAS  PubMed  Google Scholar 

  13. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 2011;13:160–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62:170–80.

    Google Scholar 

  15. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885–92.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H, et al. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. Ann Oncol. 2007;18:1893–7.

    Article  CAS  PubMed  Google Scholar 

  17. Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H, et al. Serum uric acid and risk of cancer mortality in a large prospective male cohort. Cancer Causes Control. 2007;18:1021–9.

    Article  PubMed  Google Scholar 

  18. Tanriverdi O, Cokmert S, Oktay E, Pilanci KN, Menekse S, Kocar M, et al. Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish descriptive oncological researches group. Med Oncol. 2014;31:217.

    Article  PubMed  Google Scholar 

  19. Stotz M, Szkandera J, Seidel J, Stojakovic T, Samonigg H, Reitz D, et al. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. PLoS One. 2014;9:e104730.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, et al. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer. 2013;119:2645–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Song HJ, Lee EK, Lee JA, Kim HL, Jang KW. The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis. Tumour Biol. 2014;35:8771–9.

    Article  CAS  PubMed  Google Scholar 

  22. Shin HS, Lee HR, Lee DC, Shim JY, Cho KH, Suh SY. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manag. 2006;31:493–501.

    Article  CAS  Google Scholar 

  23. Szkandera J, Gerger A, Liegl-Atzwanger B, Stotz M, Samonigg H, Ploner F, et al. Uric acid levels in blood are associated with clinical outcome in soft-tissue sarcoma patients. Clin Chem Lab Med. 2015;53:493–7.

    Article  CAS  PubMed  Google Scholar 

  24. Bacci G, Picci P, Ferrari S, Orlandi M, Ruggieri P, Casadei R, et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer. 1993;71:1224–30.

    Article  CAS  PubMed  Google Scholar 

  25. Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep. 2002;9:171–5.

    PubMed  Google Scholar 

  26. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27:608–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Preitner F, Laverriere-Loss A, Metref S, Da Costa A, Moret C, Rotman S, et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice. Am J Physiol Ren Physiol. 2013;305:F786–95.

    Article  CAS  Google Scholar 

  28. Bo S, Gambino R, Durazzo M, Ghione F, Musso G, Gentile L, et al. Associations between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction. J Endocrinol Investig. 2008;31:499–504.

    Article  CAS  Google Scholar 

  29. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis. 2007;17:409–14.

    Article  CAS  PubMed  Google Scholar 

  30. Karbowska A, Boratynska M, Kusztal M, Klinger M. Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transplant Proc. 2009;41:3052–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Orthopaedics, Second Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou, 450002, China

    Shangzeng Wang

  2. Department of Orthopaedics, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, 450002, China

    Xiaoya Liu & Zike He

  3. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China

    Xinfeng Chen

  4. Department of Medicine, Shanghai Cancer Hospital, Shanghai, 200366, China

    Wei Li

Authors
  1. Shangzeng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoya Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zike He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinfeng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoya Liu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, S., Liu, X., He, Z. et al. Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma. Tumor Biol. 37, 1205–1210 (2016). https://doi.org/10.1007/s13277-015-3830-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3830-3

Keywords

Search

Navigation